Free up your professional resources to focus on strategic priorities by allowing our dedicated evidence synthesis teams to employ this unique AI-powered literature review platform on your behalf, providing transparent and reproducible evidence faster, more efficiently, and from a greater breadth of sources than through a traditional approach to providing biopharma evidence synthesis services.
EVID AI allows us to offer:
Our other equally powerful technology platforms play an integral role in our ability to provide life sciences companies with a better way to optimize insights and evidence.
RPR is an agile, on-demand platform that leverages a network of 3,500+ payers and decision-makers in 65+ countries to provide clients with faster, higher-quality insights via direct automated stakeholder engagement which includes the ability to ask follow-up questions.
Tailored precisely to your needs, Integrated Evidence Planning (IEP) platforms provide an intuitive online solution to the complexity of evidence generation planning, management, alignment, and communication across critical stages of the product lifecycle.
Powered by primary payer research, Envision™ is a platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive EMA or FDA guidance.
Headquarters:
HOBOKEN
111 River Street, Suite 1120
Hoboken, New Jersey 07030, US
